Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- PHXM.PA
- Price
- 0.10
- Stock movement up
- +- (%)
- Company name
- PHAXIAM Therapeutics S.A.
- Exchange
- (PA ,
- Currency
- EUR )
- Sector
- Healthcare >Biotechnology
- Market cap
- 1.01M
- Ent value
- -
- Price/Sales
- -
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -94.26%
- 3 year return
- -76.16%
- 5 year return
- -71.44%
- 10 year return
- -54.63%
Last updated: 2025-09-17
DIVIDENDS
PHXM.PA does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | - |
| EV to Sales | - |
FINANCIALS
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.10 |
| Daily high | 0.12 |
| Daily low | 0.10 |
| Daily Volume | 0K |
| All-time high | 369.60 |
| 1y analyst estimate | 4.90 |
| Beta | 1.74 |
| EPS (TTM) | - |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| PHXM.PA | S&P500 | |
| Current price drop from All-time high | -99.97% | -0.26% |
| Highest price drop | -99.97% | -19.00% |
| Date of highest drop | 20 Aug 2025 | 8 Apr 2025 |
| Avg drop from high | -66.33% | -2.71% |
| Avg time to new high | 102 days | 5 days |
| Max time to new high | 2574 days | 89 days |
COMPANY DETAILS
Marketcap
1.01M
Marketcap category
Small-cap
Description
PHAXIAM Therapeutics S.A., a clinical-stage biopharmaceutical company, focuses on developing bacteriophage-based therapies for severe resistance infections in France. The company develops and commercializes red cell-based therapies for cancers and orphan diseases. It develops anti-infectious therapies based on the use of bacteriophages (phages) to treat infections caused by Escherichia coli (E.coli), Pseudomonas aeruginosa (P.aeruginosa), and Staphylococcus aureus (S.aureus). The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. The company was incorporated in 2004 and is headquartered in Lyon, France.
Employees
68
Website
Investor relations
-
SEC filings
CEO
Country
France
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found